photo of

Details

Role Group Leader / Honorary Fellow Manager
Research area Infection, Immunity and Global Health
Group Molecular Microbiology
Professor Suzanne Garland is the Group Leader of the Molecular Microbiology group at MCRI.
Professor Suzanne Garland is the Group Leader of the Molecular Microbiology group at MCRI.

Top Publications

  • Giles, ML, Garland, SM, Lewin, SR, Hellard, ME. What are the barriers to offering HIV testing in an antenatal setting? A national study of obstetricians. AIDS 21(12) : 1601 -1606 2007
    view publication
  • Stevens, MP, Garland, SM, Rudland, E, Tan, J, Quinn, MA, Tabrizi, SN. Comparison of the Digene Hybrid Capture 2 Assay and Roche AMPLICOR and LINEAR ARRAY Human Papillomavirus (HPV) Tests in Detecting High-Risk HPV Genotypes in Specimens from Women with Previous Abnormal Pap Smear Results▿. Journal of Clinical Microbiology 45(7) : 2130 -2137 2007
    view publication
  • Garland, SM, Steben, M, Hernandez-Avila, M, Koutsky, LA, Wheeler, CM, Perez, G, Harper, DM, Leodolter, S, Tang, GWK, Ferris, DG, et al. Noninferiority of Antibody Response to Human Papillomavirus Type 16 in Subjects Vaccinated with Monovalent and Quadrivalent L1 Virus-Like Particle Vaccines▿. mSphere 14(6) : 792 -795 2007
    view publication
  • Garland, SM, Hernandez-Avila, M, Wheeler, CM, Perez, G, Harper, DM, Leodolter, S, Tang, GWK, Ferris, DG, Steben, M, Bryan, J, et al. Quadrivalent Vaccine against Human Papillomavirus to Prevent Anogenital Diseases. New England Journal of Medicine 356(19) : 1928 -1943 2007
    view publication
  • Joura, EA, Leodolter, S, Hernandez-Avila, M, Wheeler, CM, Perez, G, Koutsky, LA, Garland, SM, Harper, DM, Tang, GW, Ferris, DG, et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. The Lancet 369(9574) : 1693 -1702 2007
    view publication

Page 106 of 147

Related links